New promises and challenges in the treatment of advanced non-small-cell lung cancer

The Lancet, Год журнала: 2024, Номер 404(10454), С. 803 - 822

Опубликована: Авг. 1, 2024

Язык: Английский

---

Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma

Blood, Год журнала: 2024, Номер 144(20), С. 2121 - 2135

Опубликована: Авг. 22, 2024

Язык: Английский

---

CAR T Cells and T-Cell Therapies for Cancer

JAMA, Год журнала: 2024, Номер 332(22), С. 1924 - 1924

Опубликована: Ноя. 4, 2024

Chimeric antigen receptor (CAR) T cells are lymphocytes that genetically engineered to express a synthetic recognizes tumor cell surface and causes the kill cell. CAR treatments improve overall survival for patients with large B-cell lymphoma progression-free multiple myeloma.

Язык: Английский

---

Beyond Chemoimmunotherapy in Advanced Non–Small Cell Lung Cancer: New Frontiers, New Challenges

American Society of Clinical Oncology Educational Book, Год журнала: 2024, Номер 44(3)

Опубликована: Май 23, 2024

Chemoimmunotherapy is currently the preferred first-line treatment option for majority of patients with advanced non-small cell lung cancer without driver genetic alterations. Most these patients, however, will experience disease progression within first year after initiation and both their physicians be confronted dilemma optimal second-line treatment. Identification molecular targets, such as

Язык: Английский

---

Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities

Trends in Pharmacological Sciences, Год журнала: 2024, Номер 45(6), С. 520 - 536

Опубликована: Май 13, 2024

Язык: Английский

---

Longitudinal genomic profiling using liquid biopsies in metastatic nonsquamous NSCLC following first line immunotherapy

npj Precision Oncology, Год журнала: 2025, Номер 9(1)

Опубликована: Янв. 8, 2025

Tumor genomic profiling is often limited to one or two timepoints due the invasiveness of tissue biopsies, but longitudinal may provide deeper clinical insights. Using ctDNA data from IMpower150 study, we examined genetic changes in metastatic non-squamous NSCLC post-first-line immunotherapy. Mutations were most frequently detected TP53, KRAS, SPTA1, FAT3, and LRP1B at baseline during treatment. Mutation levels rose prior radiographic progression progressing patients, with specific mutations (SPTA1, STK11, KEAP1, SMARCA4, TBX3, CDH2, MLL3) significantly enriched those nondurable response. However, ctDNA's role detecting hyperprogression pseudoprogression remains uncertain. SLT2, KEAP1 showed strongest correlation poorer overall survival, while correlated shorter progression-free survival. Overall, liquid biopsy provided valuable insights into lung cancer biology post-immunotherapy, potentially guiding personalized therapies future drug development.

Язык: Английский

---

Manganese-based immunotherapy synergized with novel supramolecular hydrogel: Advancing localized immune activation strategies in squamous cell carcinoma

Materials & Design, Год журнала: 2025, Номер unknown, С. 113632 - 113632

Опубликована: Янв. 1, 2025

Язык: Английский

---

Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures

Cell Reports Medicine, Год журнала: 2025, Номер unknown, С. 101934 - 101934

Опубликована: Фев. 1, 2025

Highlights•mTLSs are predictive of response to ICIs in NSCLC•Two CAF subsets within the TME key determinants primary resistance ICIs•FAP+αSMA+ CAFs correlate with inflammatory and exhaustion CD8+ T cells•MYH11+αSMA+ favor an immunosuppressive CD4+ Treg cell infiltrationSummaryEffectiveness immune checkpoint inhibitors (ICIs) non-small lung cancer (NSCLC) has been linked presence mature tertiary lymphoid structures (mTLSs) tumor microenvironment (TME). However, only a subset mTLS-positive NSCLC derives benefit, thus highlighting need unravel ICI determinants. The comprehensive analysis ICI-treated patients (n = 509) from Bergonié Institute Profiling (BIP) study (NCT02534649) reveals that mTLSs correlates improved clinical outcomes, independently programmed death ligand 1 (PD-L1) expression genomic features. Employing spatial transcriptomics alongside multiplex immunofluorescence (mIF), we show two distinct cancer-associated fibroblasts (CAFs) essential factors mediating NSCLC. These associated exclusion, exhaustion, increased regulatory infiltration, underscoring TME. Our highlights pivotal role specific thwarting ICIs, proposing new therapeutic targets enhance immunotherapy efficacy.Graphical abstract

Язык: Английский

---

Lung Cancer Research and Treatment: Global Perspectives and Strategic Calls to Action

Annals of Oncology, Год журнала: 2024, Номер unknown

Опубликована: Окт. 1, 2024

Язык: Английский

---

Editorial: Spatial immune cell heterogeneity in the tumor microenvironment

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Фев. 21, 2024

Citation: Ganguly A, Mukherjee S and Spada (2024) Editorial: Spatial immune cell heterogeneity in the tumor microenvironment. Front. Immunol. 15:1377532. doi: 10.3389/fimmu.2024.1377532

Язык: Английский

---